Valbiotis SA

Paris Stock Exchange ALVAL.PA

Valbiotis SA Operating Income for the year ending December 31, 2023: USD -7.90 M

Valbiotis SA Operating Income is USD -7.90 M for the year ending December 31, 2023, a 47.45% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.
  • Valbiotis SA Operating Income for the year ending December 31, 2022 was USD -15.04 M, a -21.52% change year over year.
  • Valbiotis SA Operating Income for the year ending December 31, 2021 was USD -12.38 M, a -87.12% change year over year.
  • Valbiotis SA Operating Income for the year ending December 31, 2020 was USD -6.61 M, a 15.56% change year over year.
  • Valbiotis SA Operating Income for the year ending December 31, 2019 was USD -7.83 M, a -42.93% change year over year.
Key data
Date Operating Income EBIT EBITDA Net Income
Market news
SV Wall Street
Paris Stock Exchange: ALVAL.PA

Valbiotis SA

CEO Mr. Sebastien Peltier HDR, Ph.D.
IPO Date June 7, 2017
Location France
Headquarters rue Paul Vatine
Employees 52
Sector Healthcare
Industries
Pharmaceuticals Biotechnology Clinical Trials Non-Alcoholic Beverages Pet Food Snack Foods Soft Drinks & Sodas Vaccines
Description

Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.

Similar companies

OSE.PA

OSE Immunotherapeutics SA

USD 6.79

2.49%

StockViz Staff

February 7, 2025

Any question? Send us an email